CPRX Q3 2020 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M-5.1% YoY

Gross Profit

$25M86.8% margin

Operating Income

$12M39.9% margin

Net Income

$43M147.8% margin

EPS (Diluted)

$0.41

QoQ Revenue Growth

-1.0%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

$11M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$175M

Total Liabilities

$18M

Stockholders' Equity

$157M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$31M	-5.1%
Gross Profit	$25M	$27M	-4.0%
Operating Income	$12M	$14M	-15.5%
Net Income	$43M	$14M	+218.0%